P

Inventor

SWANSON BARBARA A

US23 patents
⚠️ This page may combine multiple inventors who share the name “SWANSON BARBARA A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SORRENTO THERAPEUTICS INC

18 patents
US10058609B2Aug 28, 2018

Antigen binding proteins that bind PD-L1

SORRENTO THERAPEUTICS INC17 citations93
US9676853B2Jun 13, 2017

Antigen binding proteins that bind PD-1

SORRENTO THERAPEUTICS INC15 citations92
US10035855B2Jul 31, 2018

Antibody therapeutics that bind CD47

SORRENTO THERAPEUTICS INC8 citations84
US10377827B2Aug 13, 2019

Antigen binding proteins that bind c-met

SORRENTO THERAPEUTICS INC14 citations83
US10584168B2Mar 10, 2020

Antigen binding proteins that bind PD-1

SORRENTO THERAPEUTICS INC1 citations72
US9315579B2Apr 19, 2016

Antigen binding proteins that bind CCR2

SORRENTO THERAPEUTICS INC3 citations71
US10435476B2Oct 8, 2019

Antibody therapeutics that bind JAG1

SORRENTO THERAPEUTICS INC4 citations68
US11878058B2Jan 23, 2024

Antigen binding proteins that bind PD-L1

SORRENTO THERAPEUTICS INC0 citations62
US11242391B2Feb 8, 2022

Antigen binding proteins that bind PD-1

SORRENTO THERAPEUTICS INC0 citations62
US11027012B2Jun 8, 2021

Antigen binding proteins that bind PD-L1

SORRENTO THERAPEUTICS INC0 citations62
US11155628B2Oct 26, 2021

Antigen binding proteins that bind c-Met

SORRENTO THERAPEUTICS INC0 citations60
US10696746B2Jun 30, 2020

Antigen binding proteins that bind CCR2

SORRENTO THERAPEUTICS INC0 citations51
US9951138B2Apr 24, 2018

Antigen binding proteins that bind CCR2

SORRENTO THERAPEUTICS INC0 citations51
US9944707B2Apr 17, 2018

Antibodies that bind epidermal growth factor receptor (EGFR)

SORRENTO THERAPEUTICS INC1 citations51
US10668148B2Jun 2, 2020

Fully human anti-C-X-C chemokine receptor 3 (CXCR3) antibodies and methods of use thereof

SORRENTO THERAPEUTICS INC0 citations50
US10479837B2Nov 19, 2019

Methods for treating subjects having a CXC chemokine receptor 5 (CXCR5)-responsive cancer by administering fully human anti-CXCR5 antibodies

SORRENTO THERAPEUTICS INC0 citations50
US9765145B2Sep 19, 2017

Fully human anti-C-X-C chemokine receptor 3 (CXCR5) antibodies

SORRENTO THERAPEUTICS INC0 citations50
US9765146B2Sep 19, 2017

Fully human anti-CXC chemokine receptor 5 (CXCR5) antibodies

SORRENTO THERAPEUTICS INC1 citations50

GENENCOR INT

4 patents

ZHOU HEYUE

1 patent